English
新闻公告
More
化学进展 2001, Vol. 13 Issue (04): 283- 前一篇   后一篇

• 综述与评论 •

基质金属蛋白酶抑制剂设计的研究进展*

成峰;柳红;罗小民;蒋华良**;沈竞康;陈凯先;嵇汝运   

  1. 中国科学院上海药物研究所 上海 200031

  • 收稿日期:2000-03-01 修回日期:2000-06-01 出版日期:2001-07-24 发布日期:2001-07-24
  • 通讯作者: 蒋华良

Progress in the Design of Matrix Metalloproteinase Inhibitors

Cheng Feng;Liu Hong;Luo Xiaomin;Jiang Hualiang**;Shen Jingkang;Chen Kaixian;Ji Ruyun   

  1. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200031, China
  • Received:2000-03-01 Revised:2000-06-01 Online:2001-07-24 Published:2001-07-24
  • Contact: Jiang Hualiang
基质金属蛋白酶(MMP) 是一类含锌的水解酶, 过量的MMP会加速细胞外基质的降解并导致一系列的疾病, 例如癌症、关节炎和多发性硬化症等。因此MMP抑制剂的研究已成为药物设计研究领域中的一个热门课题。近年来, 科学家们发展了三种分子设计的方法, 包括基于底物的药物设计、基于结构的药物设计和组合化学技术。本文介绍了这些方法的原理及其在MMP抑制剂设计中的应用和进展。
Matrix metalloproteinase (MMP) is a family of zinc proteinases. The excess of these proteinases leads to the accelerated extracellular matrix degradation associated with diseases such as arthritis, cancer and multiple sclerosis. The research of MMP inhibitors is an active field of drug design. In recent years, three methods of molecular design have been developed, including substrate based design, structure based design and combinatorial chemistry technology. The principle of these methods and their applications in MMP inhibitor design are summarized in this review.

中图分类号: 

()

[ 1 ] Liotta L A , Rao C N , Wewer U M. Ann. Rev. Biochem. ,1986, 55: 1037—1057
[ 2 ] 翟中和(Zhai Z H) 等. 细胞生物学(Cytobiology). 北京: 高等教育出版社, 1995. 83—92
[ 3 ] Cawston T E, Galloway W A , Merce E, Murphy G, Reynolds J J. Biochem. J. , 1981, 195: 159—165
[ 4 ] Greene J , Wang M , Liu Y E, Raymond L A , Rosen C, Shi Y E. J. Biol. Chem. , 1996, 271: 30375—30380
[ 5 ] Massova I, Kotra L P, Fridman R, Mobashery S. Faseb. J. ,1998, 12: 1075—1095
[ 6 ] Woessner J F. Faseb. J. , 1991, 5: 2145—2154
[ 7 ] Shapiro S D, Kobayashi D K, Ley T J. J. Biol. Chem. , 1993,268: 23824—23829
[ 8 ] Takino T, Sato H, Shinagawa A , Seiki M. J. Biol. Chem. ,1995, 270: 23013—23020
[ 9 ] Will H, Hinzmann B. Eur. J. Biochem. , 1995, 231: 602- 608
[ 10 ] 赵云阁(Zhao Y G) , 欧尔比特·安尼瓦尔(Orbit Anwar) , 祝诚(Zhu C) , 生物化学和生物物理进展(Progress in Biochemistry and Biophysics) , 1999, 26: 223—228
[ 11 ] Whittaker M , Floyd C D, Brown P, Gearing A J H. Chem.Rev. , 1999, 99: 2735—2776
[ 12 ] Borkakoti N. P rog. Biophys. Mol. Biol. , 1998, 70: 73—94
[ 13 ] VanWart H E, Birkedal-Hansen H, Proc. Natl. Acad. Sci.USA , 1990, 87: 5578—5582
[ 14 ] Springman E B, Angleton E L , Birkedal-Hansen H, VanWart H E. Proc. Natl. Acad. Sci. U SA , 1990, 87: 364—368
[ 15 ] Lovejoy B, Hassell A M , L uther M A , Weigl D, Jordan S R.Biochemistry, 1994, 33: 8207—8217
[ 16 ] Johnson W H, Roberts N A , Borkakoti N. J. Enz. Inhib. ,1987, 2: 1
[ 17 ] Babine R E, Bender S L. Chem. Rev. , 1997, 97: 1359
[ 18 ] Grams F, Reinemer P, Powers J C, Kleine T, Pieper M ,Tschesche H, Huber R, Bode W. Eur. J. Biochem. , 1995,228: 830—841
[ 19 ] Castelhano A L , Billedeau R, Dewdney N , et al. Bioorg.Med. Chem. Lett. , 1995, 5: 1415
[ 20 ] Miller A , Askew M , Beckett R P, et al. Bioorg. Med.Chem. Lett. , 1997, 7: 193
[ 21 ] Maskos K, Fernandez-Catalan C, Huber R, et al. Proc. Natl.Acad. Sci. USA , 1998, 95: 3408—3412
[ 22 ] Beckett R P, Davidson A H, Drummond A H, et al. Drug Discovery Today, 1996, 1: 16
[ 23 ] Crimmin M J , Beckett P R, Davis M H. PCT Patent Application, WO 9421625, 1994 ( Chem. A bstr. , 1995, 122:188173)
[ 24 ] Gallop M A , Barrett R W , Dower W J , et al. J. Med.Chem. , 1994, 37: 1233—1251
[ 25 ] Gordon E M , Barrett R W , Dower W J , et al. J. Med.Chem. , 1994, 37: 1385—1401
[ 26 ] 麻锦彪(Ma J B) , 吴厚铭(Wu H M ). 化学进展( Progress in Chemistry) , 1999, 11: 265—274
[ 27 ] Esser C K, Kelvin N J , Yates N A , Chapman K T. Bioorg.Med. Chem. Lett. , 1997, 7: 2639
[ 28 ] Ferry G, Boutin J A , Hennig P, et al. Eur. J. Pharmacol. ,1998, 351: 225—233
[ 29 ] Rockwell A , Melden M , Copeland R A , et al. J. Am. Chem.Soc. , 1996, 118: 10337
[ 30 ] Foley M A , Hassman A S, Drewry D H, et al. Bioorg. Med.Chem. Lett. , 1996, 6: 1905
[ 31 ] Szardenings A K, Harris D, Lam S, et al. J. Med. Chem. ,1998, 41: 2194—2200
[ 32 ] Szardenings A K, A ntonenko V , Campbell D A , et al. J.Med. Chem. , 1999, 42: 1348—1357
[ 33 ] Campbell D A , Bermak J C, Burkoth T S, Patel D V. J. Am.Chem. Soc. , 1995, 117: 5381
[ 34 ] Ni Z J , Maclean D, Holmes C P, et al. J. Med. Chem. ,1996, 39: 1601- 1608
[ 35 ] Jeng A Y, Chou M , Parker D T. Bioorg. Med. Chem. Lett. ,1998, 8: 897
[ 36 ] Smith P W , Lai J Y Q , Whittington A R, et al. Bioorg. Med.Chem. Lett. , 1994, 4: 2821
[ 37 ] Hajduk P J , Meadow s R, Fesik S W. Science, 1997, 278:497- 499
[ 38 ] Hajduk P J , Sheppard G, Netteshein D G, et al. J. Am.Chem. Soc. , 1997, 119: 5818- 5827

[1] 王欣瑜, 赵富平, 张儒, 孙子茹, 刘胜男, 高清志. 抗肿瘤缺氧诱导因子-1的小分子抑制剂[J]. 化学进展, 2021, 33(12): 2259-2269.
[2] 李享, 石家愿, 邱爽, 王明芳, 刘长林*. SOD1抑制与活性氧信号转导的调控[J]. 化学进展, 2018, 30(10): 1475-1486.
[3] 叶霁青, 岳晓虹, 孙丽萍. 小分子IL-6/STAT3信号通路抑制剂[J]. 化学进展, 2016, 28(7): 1099-1111.
[4] 郭键, 贺耘, 叶新山. 唾液酸转移酶抑制剂的设计与发现[J]. 化学进展, 2016, 28(11): 1712-1720.
[5] 李晓晖*, 黄美玲, 刘丽娜, 王燕云. 环肽类组蛋白去乙酰化酶抑制剂[J]. 化学进展, 2014, 26(09): 1527-1536.
[6] 杨冬梅, 周宇涵, 常晴, 赵一龙, 曲景平. 三氟甲基烷基酮的生物活性及合成方法[J]. 化学进展, 2014, 26(06): 976-986.
[7] 章豪, 方群, 范杰. 微量组合催化剂筛选技术[J]. 化学进展, 2014, 26(04): 512-521.
[8] 郑伟, 谢琼, 陈良康, 陈建兴, 仇缀百. 双位点作用的乙酰胆碱酯酶抑制剂[J]. 化学进展, 2013, 25(11): 1973-1980.
[9] Barbara K. Dunn. 乳腺癌预防的三期临床试验:雌激素靶向药物,选择性雌激素受体调控剂和芳香酶抑制剂[J]. 化学进展, 2013, 25(09): 1429-1449.
[10] 申刚义, 于婉婷, 刘美蓉, 崔勋. 固定化酶微反应器的制备及应用[J]. 化学进展, 2013, 25(07): 1198-1207.
[11] 杜可杰, 王忆, 梁捷雯, 计亮年, 巢晖*. DNA拓扑异构酶抑制剂[J]. 化学进展, 2013, 25(04): 545-554.
[12] 伍道春, 何严萍* . 非核苷类HCV NS5B聚合酶抑制剂[J]. 化学进展, 2012, 24(11): 2255-2267.
[13] 李铁海, 郭利娜, 李中华, 王佳佳, 李静, 赵炜. O-GlcNAcase抑制剂[J]. 化学进展, 2011, 23(8): 1657-1664.
[14] 李永东, 王华, 曾丹, 郭道义, 李勋, 范小林. 尿激酶(uPA)化学合成抑制剂[J]. 化学进展, 2011, 23(8): 1683-1691.
[15] 董缙 姚硕蔚 徐云根. 肿瘤血管生成抑制剂*[J]. 化学进展, 2010, 22(10): 1993-2002.